Fig. 2.

Anti-tumor activity of adoptively transferred bispecific T cells is enhanced by CMVpp65 vaccination (A) NSG mice were injected i.v. on day 0 with 2.5 × 106 GFPffluc + LCL cells. Three days after tumor inoculation, recipient mice were injected i.v. with 2 × 106 bi-specific cells that underwent 2 rounds of CD19 stimulation. Vaccine was given by i.v. injection of peptide pulsed autologous T cells. Fourteen to seventeen days post T cell infusion, 5 × 106 pp65pepmix (B) or pp65 peptide (C) (or MP1) loaded autologous T cells were irradiated and injected (iv) into T-cell-engrafted mice as vaccine. pp65 vaccine was also supplemented to the mice that were treated with 10 × 10^{^}6 CMV-specific T cells from the same donor and untreated mice were used as another type of control. Tumor growth was evaluated by Xenogen^® imaging. n = 5 for each group in the experiments. The Mann Whitney test was used for statistical analysis.

Adopted from Wang et al. 2015 [8]